Narcolepsy Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 3.80 Billion |
| Market Size (2029) | USD 5.60 Billion |
| CAGR (2024 - 2029) | 8.04 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Narcolepsy Therapeutics Market Analysis
The Global Narcolepsy Therapeutics Market size is estimated at USD 3.80 billion in 2024, and is expected to reach USD 5.60 billion by 2029, growing at a CAGR of 8.04% during the forecast period (2024-2029).
The increasing prevalence of narcolepsy, rising narcolepsy awareness programs and services, and the presence of reimbursement policies regarding narcolepsy are significant drivers in the market. For instance, according to the journal published by the National Institute of Neurological Disorders and Strokes in January 2023, around 125,000 to 200,000 people suffered from narcolepsy in the United States in 2022. According to a January 2023 journal published by Healthline, an estimated 44.3 to 50 individuals per 100,000 in the United States were diagnosed with narcolepsy in 2022.
In addition, according to the article published by the Journal of Clinical Sleep Medicine in June 2022, an estimated 47 people per 100,000 were reported to have narcolepsy across Europe. In Germany, the incidence was estimated to be about 17.88 people per 100,000 in 2022. Such a high incidence of disorder leads to an increase in the demand and adoption of narcolepsy therapies, which is expected to drive the market's growth during the forecast period.
Market players' approval and commercialization of new drugs may also be crucial in driving market growth over the coming years. For instance, in June 2023, Avadel Pharmaceuticals PLC launched Lumryz, an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Thus, such strategic initiatives are expected to help the market to grow during the forecast period.
However, adverse effects and risks related to narcolepsy drugs and delayed diagnosis or misdiagnosis may hinder the market growth during the forecast period.
Narcolepsy Therapeutics Market Trends
The Central Nervous System Stimulants Segment is Expected to Hold a Considerable Share During the Forecast Period
Central nervous system stimulants are drugs that increase the levels of certain chemicals in the brain and increase alertness, attention, energy, and physical activity. They also increase blood pressure, heart rate, and breathing rate. Central nervous system stimulants used for attention deficit disorder, narcolepsy, or excessive sleepiness include amphetamines, methylphenidate, atomoxetine, modafinil, armodafinil, pitolisant, and solriamfetol.
The increasing use of central nervous system stimulants for treating narcolepsy, owing to their several advantages, is expected to drive the segment growth during the forecast period. For instance, according to an article published in Advances in Pharmacology in November 2023, modafinil, a central nervous system stimulant, is primarily approved for treating narcolepsy and various sleep disorders. However, due to its diverse biochemical effects, researchers have explored modafinil for additional therapeutic applications, which is expected to increase the demand for usage in sleep disorders.
Also, company activities such as product approvals and launches likely increase the availability of central nervous system stimulants for narcolepsy, boosting the segment's growth during the forecast period. For instance, in June 2024, Harmony Biosciences secured FDA approval for its supplemental New Drug Application (sNDA) concerning WAKIX (pitolisant) tablets, targeting excessive daytime sleepiness (EDS) in pediatric narcolepsy patients aged six and above. Therefore, the segment is expected to grow considerably during the forecast period due to the above-mentioned factors, such as the growing demand for central nervous system stimulants and strategic company activities.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America is expected to hold a significant share of the market during the forecast period. The growing demand for sleep disorder treatment in North America drives the market. For instance, according to the article published by Sleep Medicine: X in November 2023, in a given population, 12.6 individuals per 100,000 experienced narcolepsy with cataplexy in Canada, while 25.1 per 100,000 had narcolepsy without cataplexy in Canada in 2022. Thus, the significant burden of narcolepsy is expected to increase the need for narcolepsy treatments, boosting the market growth in the region.
Also, company activities such as acquisitions, product approvals, and regional launches are expected to grow the market significantly during the forecast period. For instance, in March 2022, Axsome Therapeutics Inc. entered a definitive agreement to acquire Sunosi (solriamfetol) from Jazz Pharmaceuticals. Sunosi is indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).
Additionally, in March 2024, Paladin Labs Inc., a subsidiary of Endo International PLC, received approval from Health Canada for its WAKIX (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged six years and older and weighing at least 30 kg with narcolepsy. Therefore, the significant burden of narcolepsy in the region and the company activities will likely boost the market growth in North America during the forecast period.
Narcolepsy Therapeutics Industry Overview
The narcolepsy therapeutics market is moderately consolidated. Collaborations and acquisitions to share technology and costs for innovation in the field are expected to be observed. The development of novel therapies and approval by international regulatory agencies drives the market. Some major players include Avadel, Harmony Biosciences (BIOPROJET), Jazz Pharmaceuticals PLC, Azurity Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.
Narcolepsy Therapeutics Market Leaders
-
Jazz Pharmaceuticals plc
-
Harmony Biosciences
-
Teva Pharmaceuticals Industries Ltd
-
Azurity Pharmaceuticals, Inc.
-
Avadel Pharmaceuticals
*Disclaimer: Major Players sorted in no particular order
Narcolepsy Therapeutics Market News
- June 2024: Harmony Biosciences secured FDA approval for its supplemental New Drug Application (sNDA) concerning WAKIX (pitolisant) tablets, targeting excessive daytime sleepiness (EDS) in pediatric narcolepsy patients aged 6 and above.
- May 2023: Avadel Pharmaceuticals PLC secured approval from the US Food and Drug Administration (FDA) for LUMRYZ. This extended-release formulation of sodium oxybate is designed for nightly consumption at bedtime. It is specifically indicated for treating cataplexy and excessive daytime sleepiness (EDS) in adults diagnosed with narcolepsy.
Global Narcolepsy Therapeutics Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Global Prevalence of Narcolepsy
4.2.2 Narcolepsy Awareness Programs, Healthcare Initiatives, and Increasing Diagnosis
4.2.3 Regulatory Support and Presence of Reimbursement Policies Regarding Narcolepsy
4.3 Market Restraints
4.3.1 Adverse Effects and Risks Related to Narcolepsy Drugs
4.3.2 Limited Treatment Options and High Costs Associated with Diagnosis, Treatment, and Narcolepsy Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Type
5.1.1 Narcolepsy with Cataplexy
5.1.2 Narcolepsy without Cataplexy
5.1.3 Secondary Narcolepsy
5.2 By Product
5.2.1 Central Nervous System Stimulants
5.2.2 Sodium Oxybate
5.2.3 Selective Serotonin Reuptake Inhibitors
5.2.4 Tricyclic Antidepressants
5.2.5 Other Products
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amneal Pharmaceuticals Inc.
6.1.2 Harmony Biosciences (BIOPROJET)
6.1.3 Jazz Pharmaceuticals PLC
6.1.4 Prasco LLC
6.1.5 Novartis AG
6.1.6 Avadel Pharmaceuticals
6.1.7 Azurity Pharmaceuticals Inc.
6.1.8 Teva Pharmaceuticals Industries Ltd
6.1.9 Axsome Therapeutics Inc.
6.1.10 Hikma Pharmaceuticals PLC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Narcolepsy Therapeutics Industry Segmentation
As per the scope of the report, narcolepsy is a long-term neurological disorder involving a decreased ability to regulate sleep-wake cycles. Symptoms include periods of excessive daytime sleepiness that last from seconds to minutes and can occur at any time. Treatment usually involves lifestyle changes, medications, and behavioral strategies.
The narcolepsy therapeutics market is segmented by type, product, and geography. By type, the market is segmented into cataplexy, without cataplexy, and secondary narcolepsy. By product, the market is segmented into central nervous system stimulants, sodium oxybate, tricyclic antidepressants, and other products. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD) for the above segments.
| By Type | |
| Narcolepsy with Cataplexy | |
| Narcolepsy without Cataplexy | |
| Secondary Narcolepsy |
| By Product | |
| Central Nervous System Stimulants | |
| Sodium Oxybate | |
| Selective Serotonin Reuptake Inhibitors | |
| Tricyclic Antidepressants | |
| Other Products |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Narcolepsy Therapeutics Market Research Faqs
How big is the Global Narcolepsy Therapeutics Market?
The Global Narcolepsy Therapeutics Market size is expected to reach USD 3.80 billion in 2024 and grow at a CAGR of 8.04% to reach USD 5.60 billion by 2029.
What is the current Global Narcolepsy Therapeutics Market size?
In 2024, the Global Narcolepsy Therapeutics Market size is expected to reach USD 3.80 billion.
Who are the key players in Global Narcolepsy Therapeutics Market?
Jazz Pharmaceuticals plc, Harmony Biosciences, Teva Pharmaceuticals Industries Ltd, Azurity Pharmaceuticals, Inc. and Avadel Pharmaceuticals are the major companies operating in the Global Narcolepsy Therapeutics Market.
Which is the fastest growing region in Global Narcolepsy Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Narcolepsy Therapeutics Market?
In 2024, the North America accounts for the largest market share in Global Narcolepsy Therapeutics Market.
What years does this Global Narcolepsy Therapeutics Market cover, and what was the market size in 2023?
In 2023, the Global Narcolepsy Therapeutics Market size was estimated at USD 3.49 billion. The report covers the Global Narcolepsy Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Narcolepsy Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Narcolepsy Therapeutics Industry Report
The Narcolepsy Market Trends report provides a comprehensive industry analysis, covering various segments such as Type, Product, and Geography. The market is segmented into Cataplexy and Without Cataplexy, along with products like Central Nervous System Stimulants, Sodium Oxybate, and Tricyclic Antidepressants. The report offers valuable industry information, highlighting industry trends and market growth.
The market research includes a detailed market overview and market segmentation, providing insights into the market leaders and market value. The report also features a market forecast and market outlook, presenting a clear picture of the market predictions and industry outlook.
Industry reports and industry research are crucial for understanding market data and market review. The report example and report pdf provide a thorough market analysis, showcasing the market size and industry size. The industry statistics and market statistics are essential for comprehending the market dynamics.
The market report and market research delve into the market trends, emphasizing the market growth rate and industry growth rate. The market review and market segmentation offer a detailed examination of the market structure and market value. The industry sales and market sales are also covered in the industry report.
Overall, this report is an indispensable resource for research companies and industry professionals seeking a deep understanding of the narcolepsy market. The report pdf is available for download, providing an easy-to-access format for further analysis and industry insights.
Global Narcolepsy Therapeutics Market Report Snapshots
